Table 1 Immunophenotypes of CIRC tumor and small cell carcinoma of this case
Antibody | Immunophenotype | ||
|---|---|---|---|
CIRC tumor | Small cell carcinoma | ||
Primary tumor | Relapsed tumor | ||
Epithelial markers | |||
CK7 | + | – | – |
CK8 | + | + | ± |
CK18 | + | + | ±(weakly) |
CAM5.2 | + | + | ± |
AE1/AE3 | + | + | ± |
EMA | + | + | + |
34βE12 | – | – | – |
PSA | – | – | – |
NKX3.1 | – | – | – |
P504S | – | – | – |
pCEA | – | – | – |
CK5/6 | – | – | – |
CK20 | – | – | – |
TTF-1 | – | – | ±(weakly) |
Napsin A | – | – | – |
p63 | – | – | – |
p40 | – | – | – |
Neuroendocrine cell markers | |||
NSE | – | – | + |
Chromogranin A | – | – | ± |
Synaptophysin | – | – | + |
CD56 | – | – | + |
Lymphoid markers | |||
CD3 | – | – | – |
CD4 | – | – | – |
CD5 | – | – | – |
CD8 | – | – | – |
CD20 | – | – | – |
CD30 (Ki-1) | – | – | – |
CD45 (LCA) | – | – | – |
CD45RO (UCHL-1) | – | – | – |
CD79a | – | – | – |
PAX5 | – | – | – |
EBER-1* | – | – | – |
FRC markers | |||
Tenascin-C | – | – | – |
Prolyl 3-hydroxylase 1 | – | – | – |
l-caldesmon | + | + | – |
Prolyl 4-hydroxylase 1 | + | + | – |
Lysyl hydroxylase 3 | + | + | – |
Transglutaminase II | + | + | – |
α-SMA | – | – | – |
FDC markers | |||
CD23 | – | – | – |
D2–40 | – | – | – |
Clusterin | – | – | – |
CNA.42 | – | – | – |
NGFR, low affinity | – | – | – |
CD21 | – | – | – |
CD35 | – | – | – |
Histiocytic/dendritic cell markers | |||
CD1a | – | – | – |
CD11c | – | – | – |
Langerin | – | – | – |
DC-SIGN | – | – | – |
DC-LAMP | – | – | – |
CD83 | – | – | – |
DEC205 | – | – | – |
S-100 | – | – | – |
CD68 | – | – | – |
Fascin | + | + | – |
Factor XIIIa | – | – | – |
Others | |||
Melan A | – | – | – |
HMB45 | – | – | – |
Desmin | – | – | – |
Vimentin | + | + | – |
CD34 | – | – | – |
CD117 | – | – | – |
ALK | – | – | – |
EGFR | < 10% | 20% | – |
p53 | 95% | 80% | – |
Ki-67 (hot spot) | > 75% | 15% | < 50% |